News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 ‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF Michael O'Riordan October 03, 2024
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2024 Shelley Wood October 01, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Daily News CVD Risk Twofold Higher in Patients With Cancer: ASPREE Michael O'Riordan September 27, 2024
News Daily News Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement Todd Neale September 26, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2024 Caitlin E. Cox September 03, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD Todd Neale September 01, 2024
News Conference News ESC 2024 RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board Shelley Wood August 31, 2024
News Conference News ESC 2024 Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER Todd Neale August 31, 2024
News Conference News ESC 2024 ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients Michael O'Riordan August 30, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News Scoring System Puts Focus on Medical Therapy Optimization in HFrEF L.A. McKeown August 13, 2024
News Daily News Acute HF Patients Live Longer When Seen by Specialists Michael O'Riordan August 09, 2024